(Q51367260)

English

Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration.

scientific article published on 16 May 2012

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Which is the best MRI marker of malignancy for atypical cirrhotic nodules: hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

liver cirrhosis

0 references

object named as

Ada Dormi

4

0 references

author name string

Rita Golfieri

1

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Luigi Grazioli

2

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Emanuela Orlando

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Vincenzo Lucidi

5

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Beniamino Corcioni

6

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Ernesto Dettori

7

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Laura Romanini

8

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Matteo Renzulli

9

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

publication date

16 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Journal of Magnetic Resonance Imaging

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

36

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

3

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

648-657

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Adult cirrhotic liver explants: precancerous lesions and undetected small hepatocellular carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Early hepatocellular carcinoma and dysplastic nodules

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

The combination of type I interferon and ribavirin has an inhibitory effect on mouse hepatitis virus infection

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Multistep human hepatocarcinogenesis: correlation of imaging with pathology

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

The impact of vascular and nonvascular findings on the noninvasive diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arte

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Hepatocellular carcinoma in the cirrhotic liver: gadolinium-enhanced 3D T1-weighted MR imaging as a stand-alone sequence for diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Hepatocellular carcinoma: correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Problems of spectrum and bias in evaluating the efficacy of diagnostic tests

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FJMRI.23685

21 January 2018

Identifiers

10.1002/JMRI.23685

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 April 2018

http://europepmc.org/abstract/MED/22592930

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51367260&oldid=2108337870"